European Parliament ITRE committee passes milestone on the path to implementing IMI2
The European Parliament's committee on industry, research and energy (ITRE) on January 24 adopted the second public-private joint venture in Innovative Medicines Initiative (IMI2), a partnership of the European Commission and trade group the European Federation of Pharmaceutical Industries and Associations (EFPIA), which has the goal of developing next generation vaccines, medicines and treatments, such as new antibiotics.
The EFPIA says it welcomes the ITRE committee’s decision last week, which marks another important milestone towards adopting the legislative package supporting the second Innovative Medicines Initiative.
The second initiative, which covers the period 2014-2024, has seen its budget rise to around 3 billion euros ($4.1 billion). IMI2 projects will help advance medical research in key areas of unmet medical need, from brain disorders to anti-microbial resistance. By working towards new treatments and improved delivery, IMI2 aims to improve “real world” care for patients, delivering the right treatment to the right patient at the right time.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze